Cargando…
743. Implementation of Beta-Lactam Therapeutic Drug Monitoring Programs in the Critically Ill: A Multicenter Mixed-Methods Study
BACKGROUND: Beta-lactam therapeutic drug monitoring (BL TDM; drug level testing) can facilitate improved outcomes in critically ill patients. Yet less than 20% of hospitals have implemented BL TDM. The purpose of this study was to characterize provider perceptions and key considerations for successf...
Autores principales: | Ausman, Sara, Boehmer, Kasey, Chitre, Pooja, Pine, Kathleen H, Abu Saleh, Omar M, Abdul-Aziz, Hafiz, Alshaer, Mohammad H, Gajic, Ognjen, Jannetto, Paul J, Mara, Kristin, Moreland-Head, Lindsay, Rivera, Christina G, Roberts, Jason, Rule, Andrew D, Scheetz, Marc H, Shepel, Kathryn, Barreto, Erin F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752377/ http://dx.doi.org/10.1093/ofid/ofac492.034 |
Ejemplares similares
-
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study
por: Barreto, Erin F., et al.
Publicado: (2021) -
318. Beta-lactam Therapeutic Drug Monitoring Improves Attainment of Target Drug Levels in Critically Ill Patients
por: Ausman, Sara, et al.
Publicado: (2023) -
Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
por: Barreto, Erin F., et al.
Publicado: (2021) -
In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects
por: Simoens, C, et al.
Publicado: (2003) -
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
por: Erba, E, et al.
Publicado: (2000)